Tumors deficient in expression of the transporter associated with antigen processing (TAP) usually fail to induce T-cell-mediated immunity and are resistant to T-cell lysis. However, we have found that introduction of the B7.1 gene into TAP-negative (TAP？) or TAP1-transfected (TAP1+) murine lung carcinoma CMT.64 cells can augment the capacity of the cells to induce a protective immune response against wild-type tumor cells. Differences in the strength of the protective immune responses were observed between TAP？ and TAP1+ B7.1 expressing CMT.64 cells depending on the doses of γ-irradiated cell immunization. While mice immunized with either high or low dose of B7.1-expressing TAP1+ cells rejected TAP？ tumors, only high dose immunization with B7.1-expressing TAP？ cells resulted in tumor rejection. The induced protective immunity was T-cell dependent as demonstrated by dramatically reduced antitumor immunity in mice depleted of CD8 or CD4 cells. Augmentation of T-cell mediated immune response against TAP？ tumor cells was also observed in a virally infected tumor cell system. When mice were immunized with a high dose of γ-irradiated CMT.64 cells infected with vaccinia viruses carrying B7.1 and/or TAP1 genes, we found that the cells co-expressing B7.1 and TAP1, but not those expressing B7.1 alone, induced protective immunity against CMT.64 cells. In addition, inoculation with live tumor cells transfected with several different gene(s) revealed that only B7.1- and TAP1-coexpressing tumor cells significantly decreased tumorigenicity. These results indicate that B7.1-provoked antitumor immunity against TAP？ cancer is facilitated by TAP1-expression, and thus both genes should be considered for cancer therapy in the future.
References
[1]
Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, et al. (2000) Strategies for immunotherapy of cancer. Adv Immunol 75: 235–282.
[2]
Seliger B, Maeurer MJ, Ferrone S (1997) TAP off–tumors on. Immunol Today 18: 292–299.
[3]
Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing machinery breakdown and tumor growth. Immunol Today 21: 455–464.
[4]
Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3: 999–1005.
[5]
Garcia-Lora A, Algarra I, Garrido F (2003) MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195: 346–355.
[6]
Attaya M, Jameson S, Martinez CK, Hermel E, Aldrich C, et al. (1992) Ham-2 corrects the class I antigen-processing defect in RMA-S cells. Nature 355: 647–649.
[7]
Salter RD, Cresswell P (1986) Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. Embo J 5: 943–949.
[8]
Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, et al. (1992) HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 255: 1264–1266.
[9]
Wei ML, Cresswell P (1992) HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356: 443–446.
[10]
Snyder HL, Bacik I, Bennink JR, Kearns G, Behrens TW, et al. (1997) Two novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex class I antigen processing. J Exp Med 186: 1087–1098.
[11]
Shi Y, Smith KD, Lutz CT (1998) TAP-independent MHC class I peptide antigen presentation to alloreactive CTL is enhanced by target cell incubation at subphysiologic temperatures. J Immunol 160: 4305–4312.
[12]
Lautscham G, Mayrhofer S, Taylor G, Haigh T, Leese A, et al. (2001) Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway. J Exp Med 194: 1053–1068.
[13]
van Hall T, Wolpert EZ, van Veelen P, Laban S, van der Veer M, et al. (2006) Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 12: 417–424.
[14]
Gabathuler R, Reid G, Kolaitis G, Driscoll J, Jefferies WA (1994) Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J Exp Med 180: 1415–1425.
[15]
Wolpert EZ, Petersson M, Chambers BJ, Sandberg JK, Kiessling R, et al. (1997) Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells. Proc Natl Acad Sci U S A 94: 11496–11501.
[16]
Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, et al. (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093–1102.
[17]
Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368–370.
[18]
Ramarathinam L, Castle M, Wu Y, Liu Y (1994) T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 179: 1205–1214.
[19]
Alimonti J, Zhang QJ, Gabathuler R, Reid G, Chen SS, et al. (2000) TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol 18: 515–520.
[20]
Yao Y, Li P, Singh P, Thiele AT, Wilkes DS, et al. (2007) Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II. Cell Immunol 246: 92–102.
[21]
Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, et al. (1994) Absence of B7-dependent responses in CD28-deficient mice. Immunity 1: 501–508.
[22]
Bluestone JA (1995) New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2: 555–559.
[23]
Johnston JV, Malacko AR, Mizuno MT, McGowan P, Hellstrom I, et al. (1996) B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J Exp Med 183: 791–800.
[24]
Steinman RM, Inaba K, Turley S, Pierre P, Mellman I (1999) Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol 60: 562–567.
[25]
De Silva AD, Boesteanu A, Song R, Nagy N, Harhaj E, et al. (1999) Thermolabile H-2Kb molecules expressed by transporter associated with antigen processing-deficient RMA-S cells are occupied by low-affinity peptides. J Immunol 163: 4413–4420.
[26]
Yu P, Spiotto MT, Lee Y, Schreiber H, Fu YX (2003) Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med 197: 985–995.
[27]
Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR (1997) Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 186: 65–70.
[28]
Bour H, Horvath C, Lurquin C, Cerottini JC, MacDonald HR (1998) Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization. J Immunol 160: 5522–5529.
[29]
Gao FG, Khammanivong V, Liu WJ, Leggatt GR, Frazer IH, et al. (2002) Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res 62: 6438–6441.
[30]
Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480–483.
[31]
Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ (1998) CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol 10: 443–448.
[32]
Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474–478.
[33]
Cohen PA, Peng L, Plautz GE, Kim JA, Weng DE, et al. (2000) CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 20: 17–56.
[34]
Bacik I, Cox JH, Anderson R, Yewdell JW, Bennink JR (1994) TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide. J Immunol 152: 381–387.
[35]
Hodge JW, Abrams S, Schlom J, Kantor JA (1994) Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54: 5552–5555.
[36]
Li XL, Zhang DQ, Wang D, Knight DS, Yin L, et al. (2008) In vivo Survivors of Transformed Mouse Ovarian Surface Epithelial Cells Display Diverse Phenotypes for Gene Expression and Tumorigenicity. Tumour Biol 29: 359–370.
[37]
Liu J, Xia X, Torrero M, Barrett R, Shillitoe EJ, et al. (2006) The mechanism of exogenous B7.1-enhanced IL-12-mediated complete regression of tumors by a single electroporation delivery. Int J Cancer 119: 2113–2118.
[38]
Hallden G, Hill R, Wang Y, Anand A, Liu TC, et al. (2003) Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 8: 412–424.
[39]
Zhang QJ, Seipp RP, Chen SS, Vitalis TZ, Li XL, et al. (2007) TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma. Int J Cancer.
[40]
Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM (1994) In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 179: 1215–1224.
